Published on Jun 18, 2012 by BenitecNews
Dr David Suhy, Director of Research & Development at Tacere Therapeutics, Inc., is a member of Benitec's Chief Investigators Group. He describes the program the Tacere has been working on to bring a triple ddRNAi cassette to a clinical trial.
this stuff (ddRNAi) is next generation up on what we've had for last 20 years. still early days but once
ReplyDeletethey fine tune it, it'll be a quantum leap better than today's standard. Moreover, scientists are also deploying it against HBV, HIV, solid tumors etc etc.
This study is quite amazing and I don't really understand why Pfizer would get it to this stage, with the posibility of a one-shot cure with nearly 100% transfection to the liver, without any toxicity even at large doses, and then just let it go. It looks like they just simply axed all the programs based in their Sandwich, Kent facility, despite the potential. How disappointing for HCV sufferers. The program is now with Benitec Biopharma, who previously had the drug before financial problems forced them to sell it to Tacere. No idea how they will finance the Phase I clinical trial due to commence next year, but fingers crossed someone else will see the value here.
ReplyDelete